<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983226</url>
  </required_header>
  <id_info>
    <org_study_id>SGOG OV5</org_study_id>
    <secondary_id>SGOG OV-05</secondary_id>
    <nct_id>NCT03983226</nct_id>
  </id_info>
  <brief_title>Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)</brief_title>
  <official_title>A Phase II, Randomized Study of Cytoreductive Surgery Combined With Niraparib Maintenance in Platinum-sensitive, Secondary Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Gynecologic Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the role of cytoreductive surgery and Niraparib
      maintenance in platinum-sensitive secondary recurrent ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This exploratory trial is to compare the efficacy of secondary cytoreductive surgery followed
      by chemotherapy and Niraparib maintenance, versus chemotherapy alone followed by Niraparib
      maintenance in patients with platinum-sensitive secondary recurrent ovarian cancer who never
      received secondary cytoreduction when recurrent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month disease non-progression rate</measure>
    <time_frame>up to 12 months after last patient randomized</time_frame>
    <description>12-month non-progression rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 24 months after last patient randomized</time_frame>
    <description>from date of randomization until the date of 3rd relapse/progression or death (whatever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment free intervals</measure>
    <time_frame>Up to 24 months after last patient randomized</time_frame>
    <description>the intervals of the ending date from system anticancer therapy to the starting date of the subsequent anticancer therapy or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately up to 24 months after last patient randomized</time_frame>
    <description>from date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day post-operative complications</measure>
    <time_frame>From the operation until after 30 days</time_frame>
    <description>surgical complications grading criteria will be adopted for evaluating the perioperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>baseline; 6 and 12 months after randomization</time_frame>
    <description>the European Organization for Research and Treatment (EORTC) core quality of life questionnaire (QLQ-C30, version 3.0) The total score (range from 0 to 1,000)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Ovarian Cancer Recurrent</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:
Procedure: Maximum effort cytoreductive surgery combined with Niraparib maintenance Drug: Platinum-based chemotherapy and Niraparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: Platinum-based chemotherapy and Niraparib</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Tumor debulking surgery (surgery in recurrent ovarian disease)</description>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>secondary cytoreduction</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...</intervention_name>
    <description>Salvage chemotherapy</description>
    <arm_group_label>No surgery</arm_group_label>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>third-line therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>Niraparib maintenance therapy</description>
    <arm_group_label>No surgery</arm_group_label>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>maintenance therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years to ≤ 75 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Patients with platinum-sensitive, secondary relapsed epithelial ovarian, primary
             peritoneal, or fallopian tube cancer, which is defined as those with platinum-free
             interval of 6 months or more.

          -  Front-line or second-line treatment may have included maintenance therapy

          -  Never received secondary cytoreductive surgery when recurrence

          -  Assessed by the experienced surgeons, complete resection of all recurrent disease is
             possible. Single or localized lesions identified by CT, or MRI, or positron emission
             tomography/computed tomography (PET/CT). PI and Co-PI reach consensus if extensive
             lesions or carcinomatosis.

          -  It can be included if single lesion outside the peritoneal cavity can be resected.

          -  No more than 3 disease lesions by central-reviewed PET/CT imaging if the participated
             center has never participated in any surgical trials on ovarian cancer before.

          -  Patients who have given their signed and written informed consent and their consent.

        Exclusion Criteria:

          -  Patients with borderline tumors as well as non-epithelial tumors.

          -  Patients for interval-debulking, or for second-look surgery, or palliative surgery
             planned.

          -  Patients whom have already undergone secondary cytoreduction for recurrent disease are
             excluded.

          -  Impossible to assess the resectability. Radiological signs suggesting complete
             resection is impossible.

          -  Patients who have received more than two previous regimen of chemotherapy (maintenance
             is not considered a third regimen).

          -  Third relapse or more.

          -  Patients with second or other malignancies who have been treated by surgery, if the
             treatment might interfere with the treatment of relapsed ovarian cancer or if major
             impact on prognosis is expected.

          -  Progression during chemotherapy or recurrence within 6 months after second-line
             platinum-based therapy

          -  Any contradiction not allowing surgery and/or chemotherapy and/or or Niraparib

          -  Accompanied by hypoxia serious chronic obstructive pulmonary disease

          -  Uncontrolled hypertension, cerebrovascular accident/ Stroke, myocardial infarct,
             unstable angina, untreated thrombosis, chronic congestive heart failure, or serious
             arrhythmia in need of medicine.

          -  Severe hepatitis, history of liver disease, nephrotic syndrome, renal insufficiency

          -  Active ulcer history, abdominal wall fistula, perforation of gastrointestinal tract,
             or Intra-abdominal abscess, or simultaneously apply treatment/prevent ulcers therapy.

          -  Uncontrolled diabetes

          -  Uncontrolled epilepsy need long-term antiepileptic treatment.

          -  Any medication induced considerable risk of surgery, e.g. estimated bleeding due to
             oral anticoagulating agents.

          -  ≥3 grade anemia, neutropenia or thrombocytopenia due to chemotherapy, and lasted for
             more than 4 weeks

          -  Patients with a known hypersensitivity to Niraparib or any of the excipients of the
             product.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tingyan Shi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Gynecologic Oncology Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rongyu Zang, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Gynecologic Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rong Jiang, M.D.</last_name>
    <phone>+862164041990</phone>
    <email>jiang.rong@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuting Luan, R.N.</last_name>
    <phone>+862164041990</phone>
    <email>yutingluan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Jiang, MD</last_name>
      <phone>+862164041990</phone>
      <email>jiang.rong@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yuting Luan, RN</last_name>
      <phone>+862164041990</phone>
      <email>yutingluan@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rongyu Zang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanling Feng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wen Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Bao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ShanghaiGOG.org</url>
    <description>Shanghai Gynecologic Oncology Group</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>reurrent Ovarian Cancer</keyword>
  <keyword>Secondary Cytoreductive Surgery</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Niraparib maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Niraparib</mesh_term>
    <mesh_term>Taxane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

